

SYNDERAI – Synthetic Data for the European Health Data Space

Webinar Thursday, 16 July 2026
14:00-15:00 CEST

Online on Teams



SYNDERAI – Synthetic Data for the European Health Data Space Agenda

- Welcome
Michael Strübin, HL7 Europe
- SYNDERAI: from idea to real impact
Kai Heitmann, HL7 Europe, xShare project
- Synthetic data for cancer research: the Phoenix Initiative
Thomas Debertshäuser, Charité
- Demonstration of EHDS example dataset visualization
Andries Hamster, Founda Health
- Q&A --
- Next steps and closing

Housekeeping

- Your facilitator: Michael Strübin
- The webinar is being recorded; recording and slides will be shared in pdf on www.hl7europe.org and www.hl7.tv
- Key parameters for your participation:
 - The system has disabled video and microphone for attendees
 - Please use reactions/emojis during the presentations
 - Please use the chat to make comments or pose questions
 - Please raise your hand if you'd like to speak
 - If you are invited to speak, we will unblock your video and microphone; please turn on your video and say who you are

SYNDERAI – Synthetic Data for the European Health Data Space Agenda

- Welcome
Michael Strübin, HL7 Europe
- SYNDERAI: from idea to real impact
Kai Heitmann, HL7 Europe, xShare project
- Synthetic data for cancer research: the Phoenix Initiative
Thomas Debertshäuser, Charité
- Demonstration of EHDS example dataset visualization
Andries Hamster, Founda Health
- Q&A --
- Next steps and closing



SYNDERAI – European Synthetic Data for the European Health Data Space




dr Kai U. Heitmann
HL7 Europe / HL7 Germany




SYNDERAI

Synthetic Data Examples – Realistic – using AI



SYNDERAI

Synthetic Data Examples – Realistic – using AI



Synthetic Data? Why?

PHASE I

- Synthetic Data: Examples – Realistic – using AI (SYNDERAI) pronounced /'sɪndəraɪ/
- Synthetic Data Examples seen in
 - **testing** and **validation** (e.g. industry proofs, connect-a-thons etc.)
 - in **education**
 - in further **implementation support** for vendors



PREAMBLE

Embracing the
Foundation



SYNDERAI and the xShare Project

PHASE I

- xShare Project Work Package
 - Project funded by the European Commission (7.8 Mio €)
 - Contributed to the advancement of HL7® FHIR® Implementation Guides (HL7 EU realm)
 - Toolbox supports proper implementation of the European Electronic Health Record exchange Format (EHRxF)

PREAMBLE

Embracing the
Foundation



European Health Data Space (EHDS)

Priority Categories



European
Patient
Summary



Laboratory
Report



(Hospital)
Discharge
Report



Medication
Prescription +
Dispense




Imaging
Report



HL7® FHIR® Implementation Guides – hl7.eu/fhir

EHDS Timeline



SYNDERAI Foundational Design

- SYNDERAI datasets are designed to ...

**represent
realistic clinical
scenarios**

including medications,
allergies, problems,
encounters, vital signs,
depending on the
covered use case

**be conformant
with HL7 FHIR
Implementation
Guides**


including IPS/EPS, EU
Laboratory Report,
Discharge Summary,
Medication Prescription
and Dispense, Imaging

**use realistic but
not real patient
data**

ensuring safety in both
development and
demonstration
environments

SYNDERAI

Synthetic Data Examples – Realistic – using AI





#1 Artifact: EU Laboratory Report

PHASE
II

- EHDS Lab Reports were the first synthetic artifacts
 - Starting October 2024, one per “fake” patient


START
Starting with
Lab Report



Generating Lab Reports

PHASE
II

- Testing, collecting and pre-compiling meta data
- Pairing clinical stories and demographics data using stratification
- Processing synthetic patient's clinical stories
- Emitting FHIR / FSH




START
Starting with
Lab Report




SYNDERAI Synthetic Data Generation

PHASE
II



European Synthetic data

- Synthea™ (Mitre)
 - US American set of synthetic data / clinical stories
 - US coding systems, e.g. RX Norm
- European Citizen Dataset
 - with addresses, contacts, closest primary provider / hospital
 - Stratified with at least gender, age
 - 172 European regions, relative population density




European Synthetic data

- Match Making
 - Find matches of EU Citizen with Synthea set with similar age, same gender etc.
- SYNDERAI geo-location of the synthetic patients + providers
 - Geo-proximity


Patient



Provider



European Synthetic data




- Demographic stratification, mapping to a clinical “story” or even a Persona



European Synthetic data

- Laboratory Report was first
- Other categories followed
- Example of using AI: generate the stratified, clinically expected, realistic reference ranges for lab values



TEST	RESULT	REFERENCE RANGE	UNIT
Cholesterol [Mass/volume] in Serum or Plasma	 146 mg/dL	125–200	mg/dL
Triglyceride [Mass/volume] in Serum or Plasma	 100.5 mg/dL	0–150	mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay	 77.8 mg/dL	0–100	mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma	 48 mg/dL	40–60	mg/dL

Synthetic Data Example Categories



Laboratory Report


**50 synthetic patients with
1432 HL7 FHIR example
instances of the European
Laboratory Report
(LAB)
(Package 2.0.0+20260318)**

...

...

SYNDERAI

Synthetic Data Examples – Realistic – using AI



Patient Summaries and more

PHASE
III

- Extending the generation process to other priority data categories
- Enhanced validation of created artifacts
- Connectathon IHE Europe / HL7 Europe (Plugathon)
- Building the pipeline from compile to publish

ARTIFACTS

Unveiling Patient Summaries ... +



European
Patient
Summary



Laboratory
Report



(Hospital)
Discharge
Report




Medication
Prescription +
Dispense




Imaging Report


SYNDERAI Synthetic Data Generation



SYNDERAI Synthetic Data Generation



SYNDERAI Synthetic Data Generation



Synthetic Data Example Categories

- Per patient one EPS, several to many LAB and some HDR



Laboratory Report

50 synthetic patients with
1432 HL7 FHIR example
instances of the European
Laboratory Report
(LAB)
(Package 2.0.0+20260318)



European Patient Summary

50 synthetic patients with
50 HL7 FHIR example
instances of the European
Patient Summary
(EPS)
(Package 2.0.1+20260514)




(Hospital) Discharge Report

31 synthetic patients with
53 HL7 FHIR example
instances of the European
Hospital Discharge Report
(HDR)
(Package 2.1.0+20260323)

SYNDERAI

Synthetic Data Examples – Realistic – using AI



European Prevalences and more

PHASE IV

- **SYNDERAI uses** Synthea™ from Mitre (US-centric)
- Analyzing conditions etc. and their frequency
- Disease prevalences are not comparable to typical European populations (US: “opium-related deaths“)
- Adaptation: replace and remove Synthea™ modules

EUROPEAN

Making the source
funds European



Category	Count
Modules newly added (EU-specific)	39
US modules removed (replaced or deprecated)	53
Modules present in both but modified	~110

European Prevalences and more

PHASE IV


- Hypertension
- Type 2 Diabetes
- COPD
- Asthma
- Stroke
- Myocardial Infarction
- Stable Ischaemic Heart Disease (IHD)
- Atrial Fibrillation
- Congestive Heart Failure (CHF)
- Chronic Kidney Disease (CKD)
- Alzheimer's Disease / Dementia
- Depression
- Anxiety Disorders
- Epilepsy
- Fibromyalgia
- Osteoarthritis
- Rheumatoid Arthritis
- Gout
- Osteoporosis
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Prostate Cancer
- Substance Use Disorders / Alcohol
- Sinusitis
- Sepsis
- Hypothyroidism
- Obesity
- Allergies
- Diabetic Retinopathy
- Adolescent Idiopathic Scoliosis (AIS)
- Haematological Oncology / Bone Marrow Transplant
- Also adapted: Medications, Procedures

EUROPEAN

Making the source
funds European



SYNDERAI Synthetic Data Generation



SYNDERAI Dashboards

- Conditions
- Medications
- Care Plans

SYNDERAI · EUROPEAN PATIENT SUMMARY · PACKAGE 2.1.0+20260514

EPS Cohort — Condition Statistics

50

PATIENTS

47

LIFETIME
TYPES

ACTIVE

267

ACTIVE
ENTRIES

ACTIVE

37

EPISODICAL
TYPES

RESOLVED

221

RESOLVED
ENTRIES

RESOLVED

9.8

AVG. PER
PATIENT


56.0

MEAN AGE
(YRS)

Lifetime Diagnoses · 47 condition types · 267 active entries

Lifetime diagnoses by patient prevalence % of N=50 patients · active clinical status

ALL Cardiovascular Infectious / Urological Mental / Neurological Musculoskeletal
Other Renal / Diabetic Respiratory



Domain distribution

265 active entries



Cardiovascular	35%	92
Renal / Diabetic	24%	63
Other	14%	37
Respiratory	10%	27
Mental / Neurological	8%	20
Musculoskeletal	6%	16
Infectious / Urological	4%	10

Synthetic Data Example List for EU LAB

 EU LAB (Bundle)
Timothy Smith (84) 

19-May-2025	View	JSON	XML
03-Feb-2025	View	JSON	XML
31-Jan-2025	View	JSON	XML
30-Jan-2025	View	JSON	XML

Show 33 more

 EU LAB (Bundle)
Hortense Gallet (58) 

15-Apr-2025	View	JSON	XML
28-Jan-2025	View	JSON	XML
09-Apr-2024	View	JSON	XML
06-Feb-2024	View	JSON	XML

Show 9 more

 EU LAB (Bundle)
Iva Kratochvílová (61) 

23-Mar-2025	View	JSON	XML
02-Feb-2025	View	JSON	XML
03-Nov-2024	View	JSON	XML
06-Oct-2024	View	JSON	XML

Show 33 more

 EU LAB (Bundle)
Meaghan Neary (65) 

16-Jul-2025	View	JSON	XML
17-Jun-2025	View	JSON	XML
20-May-2025	View	JSON	XML
29-Apr-2025	View	JSON	XML

Show 68 more

 EU LAB (Bundle)
Ludmila Vávrová (85) 

04-Dec-2024	View	JSON	XML
27-Nov-2024	View	JSON	XML
24-Nov-2023	View	JSON	XML
22-Nov-2023	View	JSON	XML

Show 17 more

 EU LAB (Bundle)
Aniela Pražmo (84) 

05-Jul-2025	View	JSON	XML
16-Jun-2025	View	JSON	XML
16-Jun-2024	View	JSON	XML
17-Jun-2023	View	JSON	XML

Show 18 more

 EU LAB (Bundle)
Alessio Fanucci (61) 

05-May-2025	View	JSON	XML
29-Apr-2024	View	JSON	XML
24-Apr-2023	View	JSON	XML
18-Apr-2022	View	JSON	XML

Show 12 more

 EU LAB (Bundle)
Maria Nohlmans (78) 

21-May-2025	View	JSON	XML
29-Jan-2025	View	JSON	XML
22-Jan-2025	View	JSON	XML
15-Jan-2025	View	JSON	XML

Show 70 more

synderai.net

AI in SYNDERAI


Maybe one day AI has learned to create data of this quality all on its own



- “Low dose” AI application
 - Appropriate **dosage** for a specific medication
 - Stratified normal **lab value ranges** based on patient’s conditions
 - **Conclusion** per lab report, based on all prior synthetic lab reports
 - **Synthesis** of hospital treatment episodes, treatment **summary**
 - **Primary Discharge Diagnoses** and **Procedure Lists**
 - **Care Plan Goals** based on patient’s conditions
 - EU prevalence fine-tuning of Synthea modules
 - Validation – GitHub issue pipeline for **iterative refinements**

Human Text in SYNDERAI

- Co-generated by the template-based generation method
- Human readable text with AI assistance
 - Especially for the Hospital Discharge Reports (HDR)
 - HDR sections typically contain text along with granular data such as codes or measurements for medication, results, diagnoses, etc.



The screenshot displays a medical report interface with two main sections. The first section, titled 'Synthesis' with an information icon, contains a text box with the text 'Severe aortic stenosis, valve replacement performed'. The second section, titled 'Hospital course note' with a list icon, contains a text box with a detailed medical note: 'Dear colleague, I am writing to inform you regarding your patient, an 81-year-old male admitted under our care for severe aortic valve stenosis. Upon admission, echocardiographic assessment confirmed critical aortic stenosis with significantly reduced valve area and elevated mean transvalvular gradient. Given his symptomatic presentation and'.

Viewing

SYNDERAI is
combined with
Example
Visualization,
supported also
by the Gravitare
Health project,
see vi7eti.net

× Laboratory Report

Patient

Name: **Smith, , Timothy,**
DOB: 10-SEP-1941 (Age: 84)
Gender: male
Address: 9 Jeffrey orchard
NW1 North Joshuaville (United
Kingdom)
ID: 8029-862360-6 (ECI)

Report

Date: 19-MAY-2025

Laboratory

dr Ample, Ex
Laboratoire Central Européenne
Boulevard du Jardin Botanique 32
1000 Brussels (Belgium)

Requested by

Evelina Children's Hospital
SE1 7 London (United Kingdom)

Specimen

Collected: 19-MAY-2025


vi7eti.net

Chemistry

Test	19-MAY-2025	Reference Range	Unit
Hemoglobin A1c/Hemoglobin.total in Blood	5.5	4.5 - 6.4	%
Glucose [Mass/volume] in Blood	131.1	70 - 140	mg/dL
Urea nitrogen [Mass/volume] in Blood	19.6	7 - 25	mg/dL
Creatinine [Mass/volume] in Blood	0.7	0.6 - 1.3	mg/dL
Calcium [Mass/volume] in Blood	9.1	8.5 - 10.5	mg/dL
Sodium [Moles/volume] in Blood	143.9	135 - 145	mmol/L
Potassium [Moles/volume] in Blood	4.7	3.5 - 5.1	mmol/L
Chloride [Moles/volume] in Blood	102.9	98 - 107	mmol/L
Carbon dioxide, total [Moles/volume] in Blood	26.5	22 - 29	mmol/L
Cholesterol [Mass/volume] in Serum or Plasma	244.9 H	0 - 200	mg/dL
Triglyceride [Mass/volume] in Serum or Plasma	490.0 H	0 - 199	mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay	119.1	0 - 130	mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma	27.8 L	40 - 100	mg/dL

Partner Viewing

Visualization
supported by
Andries Hamster
Founda Health



Partner FHIR Server

High Performance
FHIR Server
supported by Firely
Test Installation



fire.ly


Partner Validation

Fast Continuous
validation
Drift detection
Release evidence
supported by
medvertical



Records · DataOps Control Plane

scan-in-place · validate · evidence-report · drift-detection



Next Activities SYNDERAI

Synthetic Data Examples – Realistic – using AI

- Package Release 3 of Synthetic data: European focus, 1,000 "patients" with their stories
- Adding Imaging, Medication Prescription and Dispense
- Using the SYNDERAI methodology also for
 - HL7 Europe's PHOENIX Cancer Initiative synthetic data
 - Medical Informatics Initiative and Network University Medicine synthetic data
- Sustainability through Partners

Summary SYNDERAI

Synthetic Data Examples – Realistic – using AI

- European Priority Categories: Laboratory Report, Hospital Discharge Report, European (+ International) Patient Summary, Imaging, Medication
- One Synthetic European Patient Summary per patient, consistent and consecutive reports over time
- Template-driven generation from synthetic funds, “Low Dose” AI application for selected areas
- Combined with Example Visualization Options, FHIR-Server and Continuous Validation



Thank you!

**SYNDERAI – European Synthetic Data
for the European Health Data Space**



Webinar

dr Kai U. Heitmann

kai.heitmann@hl7europe.org / ceo@hl7.de

SYNDERAI – Synthetic Data for the European Health Data Space Agenda

- Welcome
Michael Strübin, HL7 Europe
- SYNDERAI: from idea to real impact
Kai Heitmann, HL7 Europe, xShare project
- Synthetic data for cancer research: the Phoenix Initiative
Thomas Debertshäuser, Charité
- Demonstration of EHDS example dataset visualization
Andries Hamster, Founda Health
- Q&A --
- Next steps and closing

Synthetic Data for Cancer Interoperability

A Phoenix Initiative prototype — prostate cancer pathways

Thomas Debertshäuser · Charité / BIH · HL7 Europe · PHOENIX Initiative

Charité University Medicine Berlin Berlin Institute of Health



<https://www.bihealth.org/de/forschung/wissenschaftliche-infrastruktur/core-units/interoperabilitaet/home/team>

Leitung



Prof. Dr. Sylvia Thun

Direktorin für Digitale Medizin und
Interoperabilität
Info

Telefon: +49 30 450 5430 71

E-Mail: sylvia.thun@charite.de



Thomas Debertshäuser

Wissenschaftlicher Mitarbeiter
Info

E-Mail: thomas.debertshaeuser@charite.de

EHDS moves the data; the Common Cancer Model adds the content

EHDS defines the exchange infrastructure and generic document types — but no disease-specific cancer content.

- **Generic priority categories** — patient summary, prescription, labs, imaging, discharge
- **No cancer data points** — staging, treatment response, progression not modelled
- **HL7 Europe Common Cancer Model** — minimal cancer model, mapped to FHIR + OMOP
- **In STU1 ballot now** — 1 Jul – 31 Aug 2026 · comments via HL7 Jira



The European Common Cancer Data Model




HL7 Europe Common Cancer Model
1.0.0-ballot - ballot 150



Home Introduction Functional Logical Implementation About Artifacts

Table of Contents > Home

This page is part of the HL7 Europe Common Cancer Model (v1.0.0-ballot: STU 1 Ballot 1) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions



set of concepts and relationships capable of representing cancer-related information across different contexts and use cases.

The scope of the initiative is to define a model that is **agnostic to cancer type** and **independent from specific technical standards**, providing a **common conceptual and logical backbone** that can be progressively extended over time.

The scope of this Implementation Guide is to document this common model and to support its implementation by providing mappings of the model to **HL7 FHIR** and to **OMOP**, enabling interoperability between primary data exchange and secondary data use in research contexts.

By defining consistent concepts, relationships, and longitudinal structures, the model enables, among other outcomes, the reconstruction of a typical cancer journey.

Making the model testable — without real data

The model has no FHIR profiles yet — so we make it testable without touching a single real record.

THE BLOCKER

No real data, no FHIR profiles yet



THE FOUNDATION

Synthetic cohorts as the testing substrate



THE PAYOFF

Validate today — vendors build with no real-data project

Synthetic cancer cohorts — a prostate prototype

Real registry data is privacy-locked and carries no ground truth. We generate calibrated, shareable cohorts instead — starting with prostate cancer.

- **Shareable & PII-free** — no data-access agreements, no ethics gates
- **Known ground truth** — the care process is designed, not inferred
- **The prototype** — Synthea pathway, males 50–60: symptoms → BPH or cancer → metastatic
- **Standards-native** — FHIR R4 · SNOMED · LOINC · dual ATC

SYNDERAI delivers this for the EHDS; the Phoenix Initiative is the cancer flavour.

Every transition is calibrated on evidence

Effect (transition)	Value	Source
PI-RADS 3 / 4 / 5 → cancer	16 / 59 / 85 %	Oerther 2021
Treatment: RP / RT / AS	57 / 16 / 16 %	HAROW (Herden 2016)
Incidental cancer at TURP	14 %	Sid Ahmed 2025
EAU risk groups (low/int/high/adv)	27 / 24 / 37 / 13 %	Xie 2021 (SEER)
Biochemical recurrence (high / low)	40 / 20 %	S3 Ch. 7
De-novo M1 (age 50–60)	6 %	SEER (Mali 2025)

Worked example — the guideline gives no number for PI-RADS→cancer; ours (16/59/85 %, Oerther 2021, patient-level) is full-text verified: exact. ~40 arrows traced this way · 25 sources · ESMO converges.

A real FHIR cohort — and you can mine it

1,112 seed-pinned FHIR R4 patients; the designed process is the ground truth you validate against.

Reproducible


seed-pinned, with FHIR provenance

Real timeline



diagnosis → recurrence → salvage over years

Process mining

directly-follows graph from the synthetic traces



48 real patient paths — from BPH to recurrence and salvage



What the generator already delivers today

Today's build already produces reproducible, standards-mapped synthetic cohorts — enough to validate the model and let vendors build without a real-data project.

Here today

- ✓ **Calibrated generator** module weights + states
- ✓ **Evidence-traced** ~40 transitions to source
- ✓ **EU terminology** SNOMED · LOINC · dual ATC
- ✓ **FHIR R4 output** reproducible cohort per run
- ✓ **Process mining** DFG + trace variants

<https://github.com/PHOENIX-Initiative-European-Cancer/synthea-eu-cancer/>

What the model can't do yet

Dimensions still to close before the synthetic cohort mirrors real prostate-cancer pathways end to end.

Still missing

- **Temporal axis** how long between events
- **S3 v8.1 depth** PSA screening · PSMA-PET · PARP
- time-to-treatment · BCR-free · time-to-mets
- **EU demographics** still US incidence · CCDM mapping
- **Progression hazards** flat, not time-dependent yet

<https://github.com/PHOENIX-Initiative-European-Cancer/synthea-eu-cancer/>

Appendix · sources & traceability

Guidelines & consensus

- EAU 2024 — doi.org/10.1016/j.eururo.2024.03.027
- S3-Leitlinie v8.1 (2025) — www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom
- ISUP grading, Egevad 2016 — doi.org/10.1111/apm.12533

Diagnostic pathway

- Oerther 2021 (PI-RADS meta) — doi.org/10.1038/s41391-021-00417-1
- PRECISION-type MRI 2020 — doi.org/10.1038/s41391-020-00290-4
- Nordström 2021 (LUTS→PCa) — doi.org/10.1016/j.euro.2020.12.004
- Irish PSA 2012 — doi.org/10.5402/2012/832109
- Taiwanese PSA 2023 — doi.org/10.1371/journal.pone.0283040
- Grey-zone PSAD 2021 — doi.org/10.1186/s12885-021-08216-6

Grading & staging

- Xie 2021 (SEER risk groups) — doi.org/10.3389/fonc.2021.646073
- NCDB grade migration 2023 — doi.org/10.1093/ncic/pkad018
- SEER <50, Mali 2025 — doi.org/10.1002/hsr2.70414
- Mathieu 2017 (ISUP validation) — doi.org/10.3389/fmed.2017.00157

Treatment & outcome

- HAROW, Herden 2016 — doi.org/10.3238/arztebl.2016.0329
- HAROW-AS, Herden 2020 — doi.org/10.1007/s00345-020-03471-x
- Sid Ahmed 2025 (incidental TURP) — doi.org/10.7759/cureus.90916
- NRW survival 2024 — doi.org/10.1016/j.clgc.2024.102289
- DE vs US survival, Winter 2016 — doi.org/10.1111/bju.13537

Epidemiology & detection

- Lower-Saxony incidence 2021 — doi.org/10.3389/fonc.2021.681006
- UrEpik, Boyle 2003 — doi.org/10.1046/j.1464-410x.2003.04369.x
- EPIC LUTS, Irwin 2009 — doi.org/10.1016/j.eururo.2009.02.026
- BPH epidemiology 2017 — doi.org/10.1016/j.ajur.2017.06.004
- LUTS & PSA, BJGP 2018 — doi.org/10.3399/bjgp18X699689
- NCDA screen-detected 2024 — doi.org/10.3399/BJGP.2024.0376

<https://confluence.hl7.org/spaces/HEU/pages/453923492/PHOENIX+Initiative>

SYNDERAI – Synthetic Data for the European Health Data Space Agenda

- Welcome
Michael Strübin, HL7 Europe
- SYNDERAI: from idea to real impact
Kai Heitmann, HL7 Europe, xShare project
- Synthetic data for cancer research: the Phoenix Initiative
Thomas Debertshäuser, Charité
- Demonstration of EHDS example dataset visualization
Andries Hamster, Founda Health
- Q&A --
- Next steps and closing

Speaker.



Andries Hamster

EVP Business Development

Background

Diagnostic Imaging, Health Information Exchange,
Interoperability Standards, IHE



EHDS / IHE / HL7 / Euridice

- Participate in HL7/IHE EU API Working group
- Participate in IHE MADO/XC-WADO profile development

 founda | EHDS DEMONSTRATOR IHE EU / HL7 EU

 **EHDS Demonstrator**
5 viewers available

AVAILABLE VIEWERS

**Patient Summary**
European Patient Summary (EPS) — allergies, medications, conditions, immunisations and vital signs at a glance.
EPS >

**Hospital Discharge Report**
Structured discharge summaries including diagnoses, procedures, medications on discharge and follow-up instructions.
HDR >

**Lab Results**
Laboratory report viewer with reference ranges, trend indicators and LOINC-coded test panels from FHIR DiagnosticReport resources.
LAB >

**Manifest Access to DICOM Objects**
MADO Analyzer — explore and inspect DICOM Key Object Selection and FHIR based manifests.
MADO >

**Web Access to DICOM Objects**
Viewer — retrieve and view DICOM images referenced by a MADO manifest object, and experiment with displaying rendered and raw images.
WADO >

© 2026 — Andries Hamster

SYNDERAI – Synthetic Data for the European Health Data Space Agenda

- Welcome
Michael Strübin, HL7 Europe
- SYNDERAI: from idea to real impact
Kai Heitmann, HL7 Europe, xShare project
- Synthetic data for cancer research: the Phoenix Initiative
Thomas Debertshäuser, Charité
- Demonstration of EHDS example dataset visualization
Andries Hamster, Founda Health

-- Q&A --

- Next steps and closing

SYNDERAI – Synthetic Data for the European Health Data Space Agenda

- Welcome
Michael Strübin, HL7 Europe
- SYNDERAI: from idea to real impact
Kai Heitmann, HL7 Europe, xShare project
- Synthetic data for cancer research: the Phoenix Initiative
Thomas Debertshäuser, Charité
- Demonstration of EHDS example dataset visualization
Andries Hamster, Founda Health
- Q&A --
- Next steps and closing

Next steps

[How did you like the webinar](#)
[Please share your feedback](#)

- Two ballots currently open:
 - European Patient Summary FHIR Implementation Guide
 - HL7 Europe Common Cancer Data Model
 - Both close on 31 August 2026
- <https://hl7europe.org/category/news/>
- Save the date: HL7 Europe Working Group Meeting





Thank you!